Libman‑Sacks Endocarditis – A Comprehensive Patient Guide

Overview

Libman‑Sacks endocarditis (LSE) is a form of non‑bacterial (sterile) verrucous endocarditis that most often occurs in patients with systemic lupus erythematosus (SLE) and, less commonly, in individuals with antiphospholipid syndrome (APS). The lesions are small, wart‑like vegetations that typically involve the ventricular or atrial surfaces of the heart valves, especially the mitral and aortic valves. Unlike infective endocarditis, LSE does not involve bacteria, fungi, or other microorganisms.

Although the condition is uncommon in the general population, it is relatively frequent among people with SLE. Autopsy series estimate that up to 40 % of patients with SLE may have silent LSE lesions, while clinically significant disease (symptoms or valve dysfunction) occurs in about 5‑10 % of those patients.

Who it affects

• Adults 20–50 years old (peak incidence corresponds with peak SLE activity).
• Women are affected more often than men, reflecting the female predominance of SLE (≈ 9:1).
• Patients with antiphospholipid antibodies, a history of thromboembolic events, or active systemic inflammation are at higher risk.

Symptoms

Many people with Libman‑Sacks endocarditis are asymptomatic and are diagnosed incidentally on echocardiography performed for another reason. When symptoms do occur, they reflect either valve dysfunction or embolic phenomena.

Cardiac‑related symptoms

• Dyspnea on exertion – shortness of breath that worsens with activity due to valve regurgitation or heart failure.
• Palpitations – irregular or rapid heartbeats secondary to arrhythmias or valve irritation.
• Chest discomfort or pressure – may mimic angina when the valve lesion interferes with coronary perfusion.
• New murmur – a soft, early‑systolic or midsystolic murmur heard on auscultation, often the first clue.
• Fatigue and reduced exercise tolerance – consequence of decreased cardiac output.

Embolic‑related symptoms

• Transient ischemic attacks (TIA) or stroke – emboli from vegetations travel to cerebral vessels.
• Peripheral emboli – sudden pain, pallor, or coldness in an extremity, sometimes with skin mottling.
• Kidney involvement – hematuria or renal infarction if emboli lodge in renal arteries.
• Vision changes – retinal artery occlusion causing sudden loss of vision.

Systemic symptoms (related to underlying disease)

• Fever, arthralgias, and rash – usually due to active SLE rather than LSE itself.
• Joint swelling, skin lesions, or oral ulcers – may accompany a flare of lupus that precipitates LSE.

Causes and Risk Factors

LSE is not caused by infection. The main pathogenic mechanisms involve immune‑mediated injury and hypercoagulability.

Primary causes

• Systemic lupus erythematosus (SLE) – the most common underlying condition. Autoimmune complexes deposit on valve leaflets, leading to inflammation and fibrin‑rich vegetations.
• Antiphospholipid syndrome (APS) – antibodies (lupus anticoagulant, anticardiolipin, anti‑β2‑glycoprotein I) promote thrombosis on valve surfaces, increasing lesion formation.
• Other autoimmune disorders – rare reports link LSE to rheumatoid arthritis, mixed connective tissue disease, and vasculitides.

Risk factors

• High disease activity in SLE (elevated anti‑dsDNA, low complement levels).
• Persistent antiphospholipid antibodies.
• Long‑standing corticosteroid or immunosuppressive therapy – may modify immune response and increase infection risk.
• Smoking, hypertension, and hyperlipidemia – they accelerate valve degeneration and may worsen vegetations.
• Family history of valve disease or autoimmune disease.

Diagnosis

Because LSE is non‑infectious, diagnosis hinges on imaging, laboratory evaluation for underlying autoimmune disease, and exclusion of infectious endocarditis.

Imaging studies

• Transthoracic echocardiography (TTE) – first‑line, detects vegetations >2 mm, assesses valve function, and screens for regurgitation or stenosis.
• Transesophageal echocardiography (TEE) – higher resolution; identifies smaller lesions (as small as 1 mm) and is preferred when TTE is inconclusive.
• Three‑dimensional echocardiography – allows precise measurement of vegetations and helps differentiate LSE from infective lesions.
• Cardiac MRI – useful for evaluating myocardial involvement and ruling out other causes of valve thickening.

Laboratory work‑up

• Autoimmune panel – ANA, anti‑dsDNA, complement C3/C4, anti‑phospholipid antibodies.
• Inflammatory markers – ESR, CRP (often elevated during lupus flares).
• Blood cultures – must be obtained to exclude infective endocarditis; they are negative in LSE.
• Complete blood count & metabolic panel – assess anemia, renal function, and electrolyte disturbances that may influence treatment.

Diagnostic criteria (clinical practice)

1. Presence of characteristic vegetations on echocardiography (usually verrucous, non‑destructive).
2. Underlying autoimmune disease (SLE or APS) confirmed by serology.
3. Negative blood cultures and absence of clinical evidence for infection.
4. No alternative cause for valve lesions (e.g., rheumatic disease, degeneration).

Treatment Options

Treatment aims to control the underlying autoimmune process, prevent embolic events, and manage valve dysfunction.

Medical therapy

• Immunosuppression
  • Hydroxychloroquine – cornerstone for SLE; reduces flare frequency and may limit vegetation formation.
  • Systemic glucocorticoids – short courses (e.g., prednisone 0.5–1 mg/kg) for acute lupus flares; taper to the lowest effective dose.
  • Steroid‑sparing agents – azathioprine, mycophenolate mofetil, or methotrexate used for long‑term disease control.
• Antithrombotic therapy
  • Low‑dose aspirin (81 mg daily) is recommended for most patients with LSE, especially if antiphospholipid antibodies are present.
  • Therapeutic anticoagulation (warfarin with INR 2–3) is indicated for patients with documented APS, prior thromboembolism, or large, mobile vegetations (>10 mm).
  • Direct oral anticoagulants (DOACs) are not routinely recommended for APS because evidence shows higher stroke risk compared with warfarin (NEJM 2018).
• Heart‑failure management – ACE inhibitors, beta‑blockers, or diuretics as per standard guidelines (ACC/AHA).

Procedural interventions

• Valve repair or replacement – indicated when vegetations cause severe regurgitation, stenosis, or recurrent emboli despite optimal medical therapy. Mechanical valves are preferred in patients requiring lifelong anticoagulation; bioprosthetic valves may be used in younger women planning pregnancy.
• Percutaneous interventions – rarely employed; reserved for patients who are poor surgical candidates and have isolated, accessible lesions.

Lifestyle and supportive measures

• Regular follow‑up with rheumatology and cardiology (every 3–6 months).
• Vaccinations (influenza, pneumococcal, COVID‑19) to reduce infection risk while on immunosuppressants.
• Smoking cessation, blood pressure control, and lipid management to protect valve integrity.

Living with Libman‑Sacks Endocarditis

While LSE can be serious, many patients lead normal lives with proper management.

Daily management tips

• Medication adherence – use a pill organizer or smartphone reminders. Never stop steroids or anticoagulants abruptly.
• Monitor symptoms – keep a symptom diary (shortness of breath, palpitations, new neurologic signs) and report changes promptly.
• Physical activity – moderate aerobic exercise (e.g., walking, swimming) is encouraged, but avoid extreme exertion if you have significant valve regurgitation.
• Hydration and diet – maintain adequate fluid intake; limit salt if you have heart failure. A heart‑healthy diet (Mediterranean style) supports overall cardiovascular health.
• Pregnancy considerations – discuss family planning with your rheumatologist. Hydroxychloroquine is safe, but warfarin must be switched to low‑molecular‑weight heparin during pregnancy.

Follow‑up schedule

1. Every 3 months: clinical assessment, blood pressure, SLE activity labs (ANA, anti‑dsDNA, complement).
2. Every 6–12 months: transthoracic echocardiogram to monitor vegetation size and valve function.
3. Whenever you develop new neurologic symptoms, chest pain, or worsening dyspnea – seek urgent evaluation.

Prevention

Because LSE is secondary to systemic autoimmune disease, primary prevention focuses on controlling the underlying condition.

• Maintain SLE remission – consistent use of hydroxychloroquine, regular rheumatology visits, and early treatment of flares.
• Screen for antiphospholipid antibodies – annual testing in SLE patients; prophylactic low‑dose aspirin if antibodies are persistent.
• Cardiovascular risk reduction – control hypertension, diabetes, and hyperlipidemia; quit smoking.
• Infection prevention – stay up to date with vaccinations, practice good hand hygiene, and avoid exposure to sick contacts while immunosuppressed.
• Regular cardiac imaging – baseline echo at SLE diagnosis, then repeat every 1–2 years or sooner if symptoms arise.

Complications

If left untreated or inadequately managed, LSE can lead to serious outcomes.

• Valve dysfunction – progressive regurgitation or stenosis may culminate in heart failure.
• Systemic embolization – stroke, transient ischemic attack, peripheral arterial occlusion, or renal infarction.
• Endocarditis‐related arrhythmias – irritative lesions can provoke atrial fibrillation or ventricular ectopy.
• Pregnancy complications – increased risk of miscarriage, pre‑eclampsia, or fetal growth restriction when antiphospholipid antibodies are present.
• Mortality – observational data indicate that SLE patients with LSE have a 2–3‑fold higher risk of cardiovascular death compared with those without valve involvement (Ann Rheum Dis 2020).

When to Seek Emergency Care

---

**References**

• Mayo Clinic. “Systemic lupus erythematosus.” mayo.org (accessed 2024).
• American College of Cardiology/American Heart Association. “2017 ACC/AHA Guideline for the Management of Heart Failure.” JACC 2017.
• Zuluaga J, et al. “Libman–Sacks endocarditis in systemic lupus erythematosus: clinical and echocardiographic features.” Ann Rheum Dis. 2020;79:1245‑1252.
• NEJM. “Rivaroxaban versus warfarin in antiphospholipid syndrome.” 2018;378:1139‑1150.
• Centers for Disease Control and Prevention. “Vaccines for people with autoimmune diseases.” cdc.gov (2023).
• World Health Organization. “Non‑communicable diseases: cardiovascular diseases.” who.int (2022).